COMMUNIQUÉS West-GlobeNewswire
-
MIMEDX Points to The New York Times Article on the Vast Benefits of Placental Tissue
08/10/2024 - 22:01 -
Rhythm Pharmaceuticals Announces New Employment Inducement Grants
08/10/2024 - 22:01 -
Crinetics Pharmaceuticals Announces Proposed Public Offering of Common Stock
08/10/2024 - 22:01 -
ImmuCell Announces Preliminary, Unaudited Sales Results for Q3 2024
08/10/2024 - 22:05 -
T2 Biosystems to Host Business Update Call on October 10, 2024
08/10/2024 - 22:05 -
Rani Therapeutics to Participate in the 2024 Maxim Healthcare Virtual Summit
08/10/2024 - 22:05 -
Myriad Genetics Announces Five Research Collaborations to Study the Use of MRD Testing in Breast Cancer
08/10/2024 - 22:05 -
ENCER Now Available on Amazon: A Game-Changer in Relief from Fatigue Related to Cancer Treatment
08/10/2024 - 22:29 -
Impact BioMedical Inc. (NYSE American: IBO) Announces IPO Participation with Strong Support from Partners and Affiliates
07/10/2024 - 14:30 -
Inozyme Pharma Announces Appointment of Biopharmaceutical Commercial Leader Erik Harris to its Board of Directors
07/10/2024 - 14:30 -
Route 92 Medical Files Patent Infringement Suit Against Q’Apel Medical
07/10/2024 - 14:33 -
FDA Approves Use of Up To Three Tubes of Biofrontera Inc.’s Ameluz (aminolevulinic acid HCI) Topical Gel, 10% In One Treatment
07/10/2024 - 14:45 -
Galecto Completes Strategic Review to Focus on Oncology and Liver Disease and Acquires Acute Myeloid Leukemia Preclinical Asset from Bridge Medicines
07/10/2024 - 14:45 -
Kronos Bio Announces Selection of Autoimmune Development Candidate for Sjögren’s Disease
07/10/2024 - 14:55 -
T2 Biosystems Announces Preliminary Third Quarter 2024 Financial Results
07/10/2024 - 15:00 -
VIVUS Announces Commercialization of QSIVA® in Sweden, Denmark, Finland, Iceland, Norway, and Poland
07/10/2024 - 15:00 -
Revolution Medicines to Deliver Multiple Presentations at the 2024 AACR-NCI-EORTC Symposium and Host Investor Webcast
07/10/2024 - 15:00 -
Biomea Fusion to Present at the 1st Annual Asian Conference on Innovative Therapies for Diabetes Management (ATTD-ASIA 2024)
07/10/2024 - 15:00 -
T2 Biosystems Announces Exclusive U.S. Agreement with Cardinal Health to Sell its FDA-Cleared Direct-From-Blood Diagnostics for Rapid Detection of Sepsis-Causing Pathogens
07/10/2024 - 15:05
Pages